source
- Analysts warn that PD-1/VEGF bispecific drugs may be better suited for liver cancer than lung cancerMany drugmakers have poured billions into PD-1/VEGF bispecific antibodies after ivonescimab beat Keytruda in a 2024 lung‑cancer trial, sparking a wave of deals and development programs. A recent C…
- ADC Therapeutics shares plunge as Phase 3 trial of Zynlonta shows high death rate despite efficacy gainADC Therapeutics reported Phase 3 data for Zynlonta combined with rituximab in a hard-to-treat blood cancer. The trial met its primary endpoint by extending progression-free survival versus standar…